 |
|
A simple, noninvasive test measures survival time in adult pulmonary hypertension
November 01, 2006Researchers have developed a simple, noninvasive way to measure right ventricular function in the heart to predict survival of adults who suffer from pulmonary hypertension.
The research appears in the first issue for November 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Paul M. Hassoun, M.D., of the Divisions of Cardiology, Pulmonary and Critical Care Medicine at Johns Hopkins Hospital in Baltimore, and 11 associates studied 63 consecutive patients with pulmonary hypertension. After right heart catheterization, these patients underwent a transthoracic echocardiogram to assess right ventricular performance in the heart.
Study participants were mostly female, white and had an average age of 55. Seventy-five percent (47 patients) met the World Health Organization's group 1 diagnostic classification of pulmonary hypertension.
Pulmonary hypertension involves progressive narrowing of the blood vessels in the lungs, which can lead to death. In 2000, 163,000 patients discharged from U.S. hospitals had been diagnosed with primary pulmonary hypertension. Although the problem is difficult to detect in a routine medical exam, doctors see more rapid clinical deterioration in patients who have the greatest degree of right ventricular dysfunction.
To assess the problem, researchers performed a test called tricuspid annular plane systolic excursion (TAPSE), which measures echocardiographic abnormalities in the tricuspid valve. Located between the heart's right atrium and right ventricle, the valve prevents the backflow of blood as it is pumped from the right atrium to the right ventricle.
"We found that a TAPSE of less than 1.8 cm was associated with a greater ventricular systolic dysfunction, as well as right heart remodeling," said Dr. Hassoun. "In addition, survival estimates at one and two years for those with pulmonary arterial hypertension were 94 percent and 88 percent, respectively, for individuals with a TAPSE of 1.8 cm or greater. If the TAPSE was less, the survival rates were 60 percent at one year and 50 percent at two years."
The researchers said that patients with a TAPSE of less than 1.8 cm, showing more advanced right ventricular dysfunction, had a dramatically reduced survival rate over the average follow-up time of 19 months. Patients with a TAPSE of less than 1.5 cm had an especially poor outcome.
"Our results suggest that TAPSE is a robust measure of right ventricular function and a powerful predictor of patient survival in pulmonary hypertension," said Dr. Hassoun.
The investigators noted that they believed the TAPSE test should be incorporated into the echocardiographic assessment of all patients were pulmonary artery hypertension.
American Thoracic Society
Study participants were mostly female, white and had an average age of 55. Seventy-five percent (47 patients) met the World Health Organization's group 1 diagnostic classification of pulmonary hypertension.
Pulmonary hypertension involves progressive narrowing of the blood vessels in the lungs, which can lead to death. In 2000, 163,000 patients discharged from U.S. hospitals had been diagnosed with primary pulmonary hypertension. Although the problem is difficult to detect in a routine medical exam, doctors see more rapid clinical deterioration in patients who have the greatest degree of right ventricular dysfunction.
To assess the problem, researchers performed a test called tricuspid annular plane systolic excursion (TAPSE), which measures echocardiographic abnormalities in the tricuspid valve. Located between the heart's right atrium and right ventricle, the valve prevents the backflow of blood as it is pumped from the right atrium to the right ventricle.
"We found that a TAPSE of less than 1.8 cm was associated with a greater ventricular systolic dysfunction, as well as right heart remodeling," said Dr. Hassoun. "In addition, survival estimates at one and two years for those with pulmonary arterial hypertension were 94 percent and 88 percent, respectively, for individuals with a TAPSE of 1.8 cm or greater. If the TAPSE was less, the survival rates were 60 percent at one year and 50 percent at two years."
The researchers said that patients with a TAPSE of less than 1.8 cm, showing more advanced right ventricular dysfunction, had a dramatically reduced survival rate over the average follow-up time of 19 months. Patients with a TAPSE of less than 1.5 cm had an especially poor outcome.
"Our results suggest that TAPSE is a robust measure of right ventricular function and a powerful predictor of patient survival in pulmonary hypertension," said Dr. Hassoun.
The investigators noted that they believed the TAPSE test should be incorporated into the echocardiographic assessment of all patients were pulmonary artery hypertension.
American Thoracic Society
Pulmonary Hypertension Current Events and Pulmonary Hypertension News RSSDrug for erectile dysfunction improves heart function in young heart-disease patients
Heart function significantly improved in children and young adults with single-ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
Key player identified in cascade that leads to hypertension-related kidney damage
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
UC San Diego researchers reverse pulmonary arterial hypertension in mouse models
Researchers at the University of California, San Diego, have identified a key protein that promotes the development of pulmonary arterial hypertension in humans and mice.
Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension
Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.
International conference on endothelin
One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET).
Pulmonary CT angiography identifies disease and injury beyond the pulmonary arteries in children
Computed tomography angiography (CTA) can identify abnormalities and injury beyond the pulmonary arteries, including broken bones and heart disease, according to a study published in the September issue of the American Journal of Roentgenology (AJR)
Taking dex can improve high altitude exercise capacity in certain climbers
Taking dexamathasone prophlyactically may improve exercise capacity in some mountaineers, according to Swiss researchers. Dexamathasone, known popularly to climbers as "dex," has been used for years to treat altitude-related symptoms in mountaineers, but has never been tested for its ability to improve exercise capacity at high altitude.
NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns.
Severe obesity increases risks of health problems during surgery
Healthcare providers must carefully consider the unique risk factors related to severe obesity in patients undergoing all types of surgery, according to an American Heart Association scientific advisory published in Circulation: Journal of the American Heart Association.
More Pulmonary Hypertension Current Events and Pulmonary Hypertension News Articles
|
Pulmonary Hypertension: A Patient's Survival Guide by Gail Boyer Hayes (Author) | |
 |
Pulmonary Hypertension (Contemporary Cardiology) by Nicholas S. Hill (Author), Nicholas S. Hill (Editor), Harrison W. Farber (Editor) This timely volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. In addition, the identification of genes associated with pulmonary hypertension has just begun to open the door to new pathophysiologic insights. The new therapies have led to significant improvements in patient function, quality of life and survival. This book will be of interest not only to cardiologists, pulmonary specialists and rheumatologists, but also many nurses and pharmacotherapists are becoming increasingly involved in the therapy of... |
 |
Identifying Pulmonary Hypertension Pulmonary Hypertension is a rare, complex disease of the heart and lungs. It most commonly strikes women in childbearing years, though it can affect all ages, races and both sexes. This program will identify what pulmonary hypertension is, and how it is treated. Though there is not yet a cure for this illness, treatments have emerged over the last decade, giving patients hope for a longer, healthier life. Meet patients who are living with pulmonary hypertension and demonstrate how to improve your quality of life. We'll also outline the genesis of the Pulmonary Hypertension Association, and illustrate the power people can have to organize, draw attention to a cause and work to improve the lives of patients and families coping with serious illnesses. This program is part of the award... |
 |
Pulmonary Hypertension Awareness Ribbon Mouse Pad by MyHeritageWear.com The Pulmonary Hypertension Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pulmonary Hypertension Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pulmonary Hypertension Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Hypertril for Pulmonary Hypertension - Normalize blood pressure levels - Bio-Enhanced Extraction Technology by HP-Hypertril A number of studies have demonstrated that increased free radical activity plays an important role in all cases of high blood pressure, because increased free radicals cause cellular damage and inactivate nitric oxide. Nitric oxide, an important molecular regulator of blood pressure, helps control blood pressure by dilating blood vessels. Antioxidants, powerful free radical scavengers, may help restore activities of nitric oxide and help to control blood pressure. This is the main theoretical basis of HypertrilTM. In addition to antioxidant activities, Hypertril also provides essential nutrients to support blood pressure control and improve circulation. In a study performed at the Institut de Cardiologie de Montreal, Canada, Hypertril demonstrated a significant reduction in MAP (Mean... |
 |
Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment by Robyn Barst (Editor) First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patients From the PAH Association, the leading experts in field Incorporates the latest AACP management guidelines Includes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical Treatment Aimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH |
 |
Balanceuticals Blood Circulator Dietary Supplement Capsules, 500 mg, 60-Count Bottle by Balanceuticals Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of medicinal rhubarb, prepared rehmannia root, common peony root, peach seed, bitter apricot seed, licorice root, scute, dun fly, gadfly, leech, June beetle, this time-honored formula is used in Chinese medicine to promote micro-circulation, increase blood flow to heart muscles, open and clear arteries, inhibit intestinal adhesion, soothe the liver, remove stasis and maintain healthy blood circulation and regular menses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. |
 |
Pulmonary Hypertension Medical Guide by Qontro Medical Guides (Author) The Pulmonary Hypertension Medical Guide is a publication which has been designed to better help readers understand Pulmonary Hypertension. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Pulmonary Hypertension. The Pulmonary Hypertension Medical Guide is highly recommended for those interested in understanding and learning more about Pulmonary Hypertension. |
 |
The Official Patient's Sourcebook on Primary Pulmonary Hypertension by James N. Parker (Editor), Philip M. Parker (Editor) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to primary pulmonary hypertension (also familial primary pulmonary hypertension; idiopathic pulmonary hypertension; primary obliterative pulmonary vascular disease; primary pulmonary vascular disease; pulmonary hypertension), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from... |
 |
A.H.P.B.A- 2005 Surgical Spring Week /DVD:19 Also With: American Hepato-Pancreato-Biliary Association (Host) A.H.P.B.A- 2005 Surgical Spring Week /DVD:19 SYMPOSIUM: Anesthesia challenges in liver transplantation - Problem based learning discussion (PBLD) . Perioperative management of OLT in a patient with elevated ICP due to fulminate hepatic failure, Porto-pulmonary hypertension in a patient for OLT-evaluation, contraindications and treatment - Dr. Alexandru Gottlieb (USA) Dr. Brian M. Parker (USA) / Dr. Michael A. E. Ramsay (USA) |
| © 2009 BrightSurf.com |